Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MarketEdge: Showing slight improvement. As of today, Amarin is under accumulation. B Bands=17, Under 20 means volatility has contracted so there could be a sharp movement (either way).
As of 07/15/2024 - Avoid the stock.
Stock is Not a Short Sale Candidate.
If you are Long; close position or monitor stock closely.
On 07/15/2024, The stock is underperforming the market over the last 50 trading days when compared to the S&P 500. The MACD-LT, an intermediate-term trend indicator, is bullish at this time. A close above $1.28 is a number to watch to confirm a trend reversal.Momentum as measured by the 9-day RSI is positive but showing signs of slowing. Over the last 50 trading sessions, there has been more volume on up days than on down days, indicating that AMRN is under accumulation, which is a bullish condition. The stock is trading below a falling 50-day moving average. A close above this moving average would be supportive of the improving conditions.
This guy, Rick Scott?
On March 19, 1997, investigators from the Federal Bureau of Investigation, the Internal Revenue Service, and the Department of Health and Human Services served search warrants at Columbia/HCA facilities in El Paso and on dozens of doctors with suspected ties to the company.[31] Eight days after the initial raid, Scott signed his last SEC report as a hospital executive. Four months later, the board of directors pressured him to resign as chairman and CEO.[32] He was succeeded by Thomas F. Frist Jr.[33] Scott was paid $9.88 million in a settlement, and left owning 10 million shares of stock then worth more than $350 million.[34][35][36] The directors had been warned in the company's annual public reports to stockholders that incentives Columbia/HCA offered doctors could run afoul of a federal anti-kickback law passed in order to limit or eliminate instances of conflicts of interest in Medicare and Medicaid.[33]
During Scott's 2000 deposition, he pleaded the Fifth Amendment 75 times.[37] In settlements reached in 2000 and 2002, Columbia/HCA pleaded guilty to 14 felonies and agreed to a $600+ million fine in what was at the time the largest health care fraud settlement in U.S. history. Columbia/HCA admitted systematically overcharging the government by claiming marketing costs as reimbursable, by striking illegal deals with home care agencies, and by filing false data about use of hospital space. It also admitted to fraudulently billing Medicare and other health programs by inflating the seriousness of diagnoses and to giving doctors partnerships in company hospitals as a kickback for the doctors referring patients to HCA. It filed false cost reports, fraudulently billed Medicare for home health care workers, and paid kickbacks in the sale of home health agencies and to doctors to refer patients. In addition, it gave doctors "loans" never intending to be repaid, free rent, free office furniture, and free drugs from hospital pharmacies.[38][7]
In late 2002, HCA agreed to pay the United States government $631 million, plus interest, and $17.5 million to state Medicaid agencies, in addition to $250 million paid up to that point to resolve outstanding Medicare expense claims.[39] In all, civil lawsuits cost HCA more than $2 billion to settle; at the time, this was the largest fraud settlement in U.S. history.[40][41]
Here’s an article on the PBM scam. I didn’t realize the motivation for PBM’s was to get around the insurance company 15% profit cap.
https://thehill.com/opinion/healthcare/4768725-drug-prices-pbm-rebates/
Medicare Advantage is not the government, it’s private.
Medicare Advantage plans are the perfect storm of insurance grift. They scam money out of patients, taxpayers, and medical providers.
Not long after we signed up with Aetna, we started getting calls about having a Dr come to our home for a free checkup. We declined but kept getting the calls which tended to be hard sell and annoying. Didn’t seem right and I didn’t understand the motivation. Well, now I do. Per the WSJ investigation, Medicare Advantage insurers have scammed Medicare $50B with unnecessary or inappropriate treatments and procedures.
https://www.wsj.com/health/healthcare/medicare-health-insurance-diagnosis-payments-b4d99a5d
Medicare Advantage should be done away with. Why isn’t this a bipartisan issue?
The 50% thing took effect this year so may reevaluate come October.
Other than the Vascepa, it’s not too bad. No copay on tier 1-2 or dr visits. No premium payment. It’s a pain to switch if it ends up forcing you to change health systems and get new drs, etc., plus learning to navigate a different insurance company’s Byzantine procedures. A Medicare medigap plan plus a part D plan has more consistent coverage and no out of network issues, but the monthly premiums run can run over $200/month.
My plan charges 50%, so more like $510 for 90 days (tier 4).
My thinking is that if Hikma loses the case and required to explicitly state limitations on their label, plausible deniability can no longer be claimed and it’s game over for everybody.
Came up on my Amarin ticker Apple feed yesterday.
Do you have a Medicare Advantage plan? We have Aetna Medicare Premium Plus 1 (PPO), part of CVS, and far as I know Vascepa is still on the formulary and the generic is not offered.
If the result of the lawsuit is that the generic is required to state on their label the limitations on usage, plausible deniability is over for everyone in the system.
I’m intrigued by the timing of the 2nd Qtr report and the BRAVE poster at AAIC 2024 conference. My fever dream is Amarin announces a collaboration with VA and UW Madison to conduct a larger trial based on encouraging results from BRAVE.
I’m 100% certain they will go to the supreme court.
Buyback charging out of the gate like strong bull!
You seem quite sure about this. Kindly prove how you know that Sarissa is shorting?
Take a moment to study WPRT. They did a 10:1 reverse split about a year ago. Before the split my cost basis was $2.00. Get back to me with your estimate of when they will hit $20.00. Currently at $5.70.
The only conclusion I draw from this is wait to buy shares until indicators turn positive. MarketEdge is a TA algorithm. Fundamentals and catalysts are not considered. I don’t subscribe to FFS’s perspective because I’m not a trader. That said, if you are looking to establish or liquidate a position, you might as well do it when the wind is at your back.
It looks like a typo. MarketEdge buy stop is $1.39.
MarketEdge:
As of 06/17/2024 - Stock shows Strongly Deteriorating Conditions. SCORE = 0
If you are Long, consider closing position or monitor stock closely.
Stock has indications of becoming a Short Sales Candidate; Wait for Short Signal.
On 06/17/2024, The stock is underperforming the market when compared to the S&P 500 over the last 50 trading days. If the stock closes below $1.39 a change in trend will be confirmed.Upside momentum, as measured by the 9-day RSI, is negative. Over the last 50 trading sessions, there has been more volume on down days than on up days, indicating that AMRN is under distribution, which is a bearish condition. The stock is trading below a falling 50-day moving average which confirms the deteriorating technical condition of AMRN. In addition, AMRN is below its declining 200-day moving average.
This seems like a frivolous lawsuit. Likely will take a long time to move through the courts.
100% agree. Two things at play. 1) Budget pressures. 2) Societal malaise towards heart disease. It just doesn’t provoke fear anymore in the general population. Some is ageism, like old people die and that’s normal, you got to die from something. Some is the sudden nature, either you are dead or you survive and go on living a normal life and accepting the medical bafflegab telling you your drugs are effective. Cancer is a much different story. Doctors throw everything they can at it and patients demand it. Over half the people in this country aren’t aware that heart disease is the leading cause of death. The idea that more trial evidence is needed is ludicrous.
Didn’t analysis of RI data look at participants who for one reason or another couldn’t or didn’t take a statin yet results were similar? Seems like there are other IPE studies w/o statins as well.
My BMI is 21.6. Went for a 4.5 mile walk yesterday. Couple hikes in the mountains last week. 1.5 mile run today. LDL less than 100. On Vascepa 6 years. Can’t take statins.
The article, if you read it, discusses 2013 risk equations vs. 2023 risk equations. Using the new equations, the number of people recommended for statins would drop from 45.4 million to 28.3 million. Yet heart disease is the leading cause of death. Less than half of the people in this country don’t know that. Apparently statins aren’t a magic bullet. If they were, no way would the research show they should be prescribed about half as much. Perhaps the cholesterol conjecture is flawed. By the way, I’m sure either risk equation would have flagged you.
930,000 deaths in 2021. Nice of you to mention lifestyle including diet and exercise. Great for the one person out of a thousand who takes that advice.
Heart disease continues to worsen. The authorities suggest statins are over prescribed, by a lot. What does that tell you about statin efficacy?
https://www.statnews.com/2024/06/10/cardiovascular-disease-statins-aha-guidelines/
Reverse split is a proven technique to screw the current investors and create an attractive entry point for gullible new investors.
When our Aetna Medicare Advantage plan changed copay from $100 to 50% starting this beginning of 2024, that may have hinted at things to come. Amarin may have known since then what was coming.
So you’re saying that generics are canoodling to pool their buying power with API suppliers?
So, with all those fantastic risk reduction methods, how’s the heart disease trend in Germany going these days?
The drain seems to be getting smaller by the minute.
MarketEdge today: Amarin upgraded from “Avoid” to “Neutral”
As of 05/24/2024 - Stock shows Mildly Improving Conditions. SCORE = 2
If you are Short this stock, hold position. Do not initiate new Short Sale.
Stock is not a Buy Candidate.
On 05/24/2024, Over the last 50 trading days, when compared to the S&P 500, the stock has performed in line with the market. A close above $1.43 is a number to watch to confirm a trend reversal.The stock is in a short-term oversold condition based on a Slow % K stochastic reading of 20 or lower. Over the last 50 trading sessions, there has been more volume on up days than on down days, indicating that AMRN is under accumulation, which is a bullish condition. The 50-day moving average is pointed up but the stocks is trading below this important resistance level. A move above this would further validate the improving technical condition.
Japanese population if you recall.
MarketEdge: Some signs of improvement.
As of 05/14/2024 - Caution; Stock is moving Against Opinion (moving against opinion means turning positive despite negative TA indicators)
On 05/14/2024, The stock has underperformed the market when compared to the S&P 500 over the last 50 trading days. Over the last 50 trading sessions, there has been more volume on up days than on down days, indicating that AMRN is under accumulation. The stock is trading below a falling 50-day moving average which confirms the weak technical condition of AMRN. In addition, AMRN is below its falling 200-day moving average.
Great news for the heart disease and obesity industrial complexes!
https://www.nbcnews.com/health/heart-health/adults-us-heart-diabetes-syndrome-risk-research-rcna151215
I don’t know.
Here is a study of branded EPADEL vs. generic from 2020.
https://www.scirp.org/journal/paperinformation?paperid=103416
Methods and Results: We investigated the differences in the serum levels of EPA, docosahexaenoic acid (DHA) and arachidonic acid (AA), and the EPA/AA ratios through blood sampling six months after daily administration of 1800 mg of EPADEL and a generic EPA drug was initiated for 96 patients with cardiovascular diseases. All patients received these PUFA treatments while continuing with baseline therapy. After 6 months of administration, EPADEL produced better results than the generic (G) product.
Trust me, there’s going to be enough heart disease to go around for everybody.
Good news for the future of Amarin and Vascepa I guess.
https://www.nbcnews.com/health/heart-health/adults-us-heart-diabetes-syndrome-risk-research-rcna151215
Probably. Thanks.